A combination of (ω-3) polyunsaturated fatty acids, polyphenols and L-carnitine reduces the plasma lipid levels and increases the expression of genes involved in fatty acid oxidation in human peripheral blood mononuclear cells and HepG2 cells

Ann Nutr Metab. 2011;58(2):133-40. doi: 10.1159/000327150. Epub 2011 Apr 29.

Abstract

Background: Hyperlipidemia and obesity are associated with metabolic syndrome and increased risk in developing diabetes and cardiovascular disease. Nutritional supplements, e.g. L-carnitine and polyunsaturated fatty acids (PUFAs), exert lipid-lowering effects. Hence, the hypothesis that dietetic intervention reduces plasma lipid levels and metabolic enzymes in overweight hyperlipidemic subjects was tested.

Subjects and methods: In a prospective placebo-controlled double-blind study in 22 moderately hyperlipidemic obese humans consuming low-fat yoghurt enriched with a combination of low-dose PUFAs, polyphenols and L-carnitine (PPC) twice a day for 12 weeks were compared to 20 matching participants ingesting low-fat yoghurt. The effects on plasma lipids and expression of enzymes involved in regulation of fatty acid oxidation in peripheral blood mononuclear cells (PBMCs) and HepG2 cells were evaluated.

Results: PPC consumption led to significantly reduced plasma free fatty acid (-29%) and triglyceride (-24%) concentrations (each p < 0.05). PPC application increased significantly peroxisome proliferator-activated receptor α (PPARα) mRNA abundances and those of PPARα target genes (carnitine palmitoyltransferases-1, CPT1A and CPT1B, carnitine acetyltransferase and organic cation transporter 2; each p < 0.05) in PBMCs. In controls, plasma lipid levels and PBMC gene expression did not change. These findings were substantiated by the results of cell culture experiments in HepG2 cells.

Conclusion: Supplementation of PPC had marked lipid-lowering effects and PBMC gene expression profiles seemed to reflect nutrition-related metabolic changes.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Carnitine / administration & dosage
  • Carnitine / metabolism
  • Carnitine / therapeutic use*
  • Double-Blind Method
  • Fatty Acids / metabolism*
  • Fatty Acids, Omega-3 / administration & dosage
  • Fatty Acids, Omega-3 / metabolism
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Flavonoids / administration & dosage
  • Flavonoids / metabolism
  • Flavonoids / therapeutic use*
  • Functional Food / analysis
  • Hep G2 Cells
  • Hepatocytes / metabolism
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / diet therapy
  • Hyperlipidemias / metabolism
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / metabolism
  • Leukocytes, Mononuclear / metabolism*
  • Lipids / blood*
  • Male
  • Middle Aged
  • Overweight / complications
  • Oxidation-Reduction
  • PPAR alpha / genetics
  • PPAR alpha / metabolism
  • Phenols / administration & dosage
  • Phenols / metabolism
  • Phenols / therapeutic use*
  • Polyphenols
  • RNA, Messenger / metabolism
  • Up-Regulation*

Substances

  • Fatty Acids
  • Fatty Acids, Omega-3
  • Flavonoids
  • Hypolipidemic Agents
  • Lipids
  • PPAR alpha
  • Phenols
  • Polyphenols
  • RNA, Messenger
  • Carnitine